Showing 1 - 8 results of 8 for search 'Simon Spazzapan', query time: 0.03s Refine Results
  1. 1
    KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer

    KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer by Elena Muraro, Mariangela De Zorzi, Gianmaria Miolo, Davide Lombardi, Simona Scalone, Simon Spazzapan, Samuele Massarut, Tiziana Perin, Riccardo Dolcetti, Riccardo Dolcetti, Riccardo Dolcetti, Riccardo Dolcetti, Agostino Steffan, Valli De Re

    Published 2022-01-01
    Get full text
    Article
  2. 2
    Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer

    Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer by Elena Muraro, Carlo Furlan, Michele Avanzo, Debora Martorelli, Elisa Comaro, Aurora Rizzo, Damiana A. Fae’, Massimiliano Berretta, Loredana Militello, Alessandro Del Conte, Simon Spazzapan, Riccardo Dolcetti, Riccardo Dolcetti, Marco Trovo’

    Published 2017-11-01
    Get full text
    Article
  3. 3
    Dysmetabolic Circulating Tumor Cells Are Prognostic in Metastatic Breast Cancer

    Dysmetabolic Circulating Tumor Cells Are Prognostic in Metastatic Breast Cancer by Giulia Brisotto, Eva Biscontin, Elisabetta Rossi, Michela Bulfoni, Aigars Piruska, Simon Spazzapan, Cristina Poggiana, Riccardo Vidotto, Agostino Steffan, Alfonso Colombatti, Wilhelm T. S. Huck, Daniela Cesselli, Rita Zamarchi, Matteo Turetta, Fabio Del Ben

    Published 2020-04-01
    Get full text
    Article
  4. 4
    Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patients

    Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patients by Elena Muraro, Fabio Del Ben, Matteo Turetta, Daniela Cesselli, Daniela Cesselli, Michela Bulfoni, Rita Zamarchi, Elisabetta Rossi, Elisabetta Rossi, Simon Spazzapan, Riccardo Dolcetti, Riccardo Dolcetti, Riccardo Dolcetti, Riccardo Dolcetti, Agostino Steffan, Giulia Brisotto

    Published 2022-08-01
    Get full text
    Article
  5. 5
    First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study

    First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study by Debora Basile, Lorenzo Gerratana, Carla Corvaja, Giacomo Pelizzari, Giorgia Franceschin, Elisa Bertoli, Lorenza Palmero, Diego Zara, Martina Alberti, Silvia Buriolla, Lucia Da Ros, Marta Bonotto, Mauro Mansutti, Simon Spazzapan, Marika Cinausero, Alessandro Marco Minisini, Gianpiero Fasola, Fabio Puglisi

    Published 2021-06-01
    Get full text
    Article
  6. 6
    The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.

    The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. by Stefania Gori, Alessandro Inno, Elena Fiorio, Jennifer Foglietta, Antonella Ferro, Marcella Gulisano, Graziella Pinotti, Marta Gubiotti, Maria Giovanna Cavazzini, Monica Turazza, Simona Duranti, Valeria De Simone, Laura Iezzi, Giancarlo Bisagni, Simon Spazzapan, Luigi Cavanna, Chiara Saggia, Emilio Bria, Elisabetta Cretella, Patrizia Vici, Daniele Santini, Alessandra Fabi, Ornella Garrone, Antonio Frassoldati, Laura Amaducci, Silvana Saracchini, Lucia Evangelisti, Sandro Barni, Teresa Gamucci, Lucia Mentuccia, Lucio Laudadio, Alessandra Zoboli, Fabiana Marchetti, Giuseppe Bogina, Gianluigi Lunardi, Luca Boni

    Published 2015-01-01
    Get full text
    Article
  7. 7
    Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.

    Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. by Stefania Gori, Alessandro Inno, Elena Fiorio, Jennifer Foglietta, Antonella Ferro, Marcella Gulisano, Graziella Pinotti, Marta Gubiotti, Maria Giovanna Cavazzini, Monica Turazza, Simona Duranti, Valeria De Simone, Laura Iezzi, Giancarlo Bisagni, Simon Spazzapan, Luigi Cavanna, Chiara Saggia, Emilio Bria, Elisabetta Cretella, Patrizia Vici, Daniele Santini, Alessandra Fabi, Ornella Garrone, Antonio Frassoldati, Laura Amaducci, Silvana Saracchini, Lucia Evangelisti, Sandro Barni, Teresa Gamucci, Lucia Mentuccia, Lucio Laudadio, Alessandra Zoboli, Fabiana Marchetti, Giuseppe Bogina, Gianluigi Lunardi, Luca Boni

    Published 2015-01-01
    Get full text
    Article
  8. 8
    Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

    Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study by Marina Elena Cazzaniga, Paolo Pronzato, Domenico Amoroso, Antonio Bernardo, Laura Biganzoli, Giancarlo Bisagni, Livio Blasi, Emilio Bria, Francesco Cognetti, Lucio Crinò, Michelino De Laurentiis, Lucia Del Mastro, Sabino De Placido, Alessandra Beano, Francesco Ferraù, Silva Foladore, Rosachiara Forcignanò, Teresa Gamucci, Ornella Garrone, Alessandra Gennari, Monica Giordano, Francesco Giotta, Filippo Giovanardi, Luciano Latini, Lorenzo Livi, Paolo Marchetti, Rodolfo Mattioli, Andrea Michelotti, Filippo Montemurro, Carlo Putzu, Ferdinando Riccardi, Giuseppina Ricciardi, Emanuela Romagnoli, Giuseppina Sarobba, Simon Spazzapan, Pierosandro Tagliaferri, Nicola Tinari, Giuseppe Tonini, Anna Turletti, Claudio Verusio, Alberto Zambelli, Giorgio Mustacchi

    Published 2023-12-01
    Get full text
    Article

Search Tools: